Simone Celant

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 15, 2026

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.

Journal: Annals of hematology

Published: June 30, 2025

Withdrawal notice to .

Withdrawal notice to .

Journal: The Lancet regional health. Europe

Published: October 24, 2024

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Journal: The Lancet regional health. Europe

Published: July 22, 2024

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.

Journal: British journal of haematology

Published: June 23, 2024

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].

Journal: The Lancet regional health. Europe

Published: May 30, 2024

Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry.

Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry.

Journal: ESMO open

Published: March 07, 2024

Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.

Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.

Journal: The Lancet regional health. Europe

Published: January 30, 2024

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.

Journal: HemaSphere

Published: January 06, 2024

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.

Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.

Journal: Journal of the American Heart Association

Published: October 18, 2023

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.

Journal: The Lancet regional health. Europe

Published: May 09, 2023

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.

Journal: Blood cancer journal

Published: March 23, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026